Physician profile

Brian A Link

Urology · Oklahoma City, OK

NPI 1023167798

$6,669.33

in general payments reported to CMS, 2019-2025

47 companies · $953 in 2025

The $953 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,105.49
Education$35.06

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $1,878.66 2019-2020
Astellas Pharma US INC $793.09 2019-2025 Xtandi, Myrbetriq
Boston Scientific Corporation $440.52 2019-2025 Ams 700, Ams 700 Cxr Rte Kit, Advance Xp
Medtronic, INC. $279.11 2022-2025 Interstim
Pfizer INC. $274.74 2019-2025
Abbvie INC. $249.36 2019-2025
Janssen Biotech, INC. $240.83 2019-2022
Antares Pharma, INC. $190.51 2019-2025 Xyosted, Nocdurna, Tlando
Urogen Pharma, INC. $189.71 2021-2025 Jelmyto
Myovant Sciences INC. $187.80 2021-2022
Biotissue Holdings INC. $166.74 2025
Palette Life Sciences, INC. $157.35 2022
Teleflex LLC $107.66 2021-2025 Urolift, Barrigel
Urovant Sciences INC $91.09 2021-2022
Axonics, INC. $84.82 2021-2023 Axonics
Show all 47 companies
CompanyGeneral paymentsYearsTop products
Sumitomo Pharma America, INC. $82.35 2023-2024 Gemtesa, Orgovyx
Coloplast Corp $77.55 2022-2024 Speedicath
Telix Pharmaceuticals $75.76 2023-2025 Illuccix
Allergan, INC. $74.43 2019-2021
Merck Sharp & Dohme LLC $68.90 2021-2023 Lynparza, Keytruda
Travere Therapeutics, INC. $64.94 2019-2021
Novartis Pharmaceuticals Corporation $61.75 2025
Bayer Healthcare Pharmaceuticals INC. $61.70 2020-2025
Agiliti Surgical, INC. $57.63 2020
Ferring Pharmaceuticals INC. $54.39 2024-2025 Adstiladrin
Tolmar Pharmaceuticals, INC. $53.21 2019-2022
Neotract INC. $51.50 2019-2020
Photocure INC $43.80 2020-2025 Cysview
Progenics Pharmaceuticals, INC. $43.01 2024-2025
Dendreon Pharmaceuticals LLC $41.35 2024-2025 Provenge
Endo Pharmaceuticals INC. $37.93 2020-2022
Accord Healthcare, INC. $37.58 2024
Ethicon US, LLC $37.06 2019-2024 Vistaseal, Monocryl
Vertex Pharmaceuticals Incorporated $36.87 2025
Blue Earth Diagnostics $36.72 2020-2022
Astrazeneca Pharmaceuticals Lp $35.06 2025 Imfinzi
Tolmar, INC. $30.97 2024-2025 Eligard, Jatenzo
Sagent Pharmaceuticals $25.28 2021
Clarus Therapeutics INC. $22.92 2021
Myriad Genetic Laboratories, INC. $20.63 2024 Prolaris
C. R. Bard, INC. & Subsidiaries $19.99 2023 Bard Urinary Drainage Bag
Immunitybio, INC. $16.56 2024
Zyla Life Sciences, INC. $15.50 2019
Procept Biorobotics Corporation $14.57 2022
Caldera Medical, INC $13.14 2021
Verity Pharmaceuticals INC. $13.04 2022
Medtronic USA, INC. $11.25 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Brian A Link

$6,669.33

in general payments reported 2019-2025

Years
2019-2025
Top company
Intuitive Surgical, INC.
Context
The $953 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

https://glasscript.com/doctor/731/brian-a-link

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.